These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
814 related articles for article (PubMed ID: 20683054)
1. Trastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II results. Michalaki V; Fotiou S; Gennatas S; Gennatas C Anticancer Res; 2010 Jul; 30(7):3051-4. PubMed ID: 20683054 [TBL] [Abstract][Full Text] [Related]
2. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. Schaller G; Fuchs I; Gonsch T; Weber J; Kleine-Tebbe A; Klare P; Hindenburg HJ; Lakner V; Hinke A; Bangemann N J Clin Oncol; 2007 Aug; 25(22):3246-50. PubMed ID: 17577021 [TBL] [Abstract][Full Text] [Related]
3. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. Bartsch R; Wenzel C; Altorjai G; Pluschnig U; Rudas M; Mader RM; Gnant M; Zielinski CC; Steger GG J Clin Oncol; 2007 Sep; 25(25):3853-8. PubMed ID: 17679724 [TBL] [Abstract][Full Text] [Related]
4. Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer. Chan A; Conte PF; Petruzelka L; Tubiana-Mathieu N; Ganju V; Llombart A; Espie M; Majois F; Gil MG; Vaissiere N; Villanova G Anticancer Res; 2013 Jun; 33(6):2657-64. PubMed ID: 23749924 [TBL] [Abstract][Full Text] [Related]
5. Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results. Michalaki V; Gennatas S; Gennatas K Anticancer Drugs; 2009 Mar; 20(3):204-7. PubMed ID: 19174694 [TBL] [Abstract][Full Text] [Related]
6. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. Wardley AM; Pivot X; Morales-Vasquez F; Zetina LM; de Fátima Dias Gaui M; Reyes DO; Jassem J; Barton C; Button P; Hersberger V; Torres AA J Clin Oncol; 2010 Feb; 28(6):976-83. PubMed ID: 20038734 [TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: findings from a case series. Ardavanis A; Tryfonopoulos D; Orfanos G; Karamouzis M; Scorilas A; Alexopoulos A; Rigatos G Onkologie; 2005 Nov; 28(11):558-64. PubMed ID: 16249641 [TBL] [Abstract][Full Text] [Related]
8. A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial. Yamamoto D; Iwase S; Kitamura K; Odagiri H; Yamamoto C; Nagumo Y Cancer Chemother Pharmacol; 2008 Mar; 61(3):509-14. PubMed ID: 17516068 [TBL] [Abstract][Full Text] [Related]
9. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. von Minckwitz G; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; Untch M J Clin Oncol; 2010 Apr; 28(12):2015-23. PubMed ID: 20308671 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer. Osako T; Ito Y; Takahashi S; Tokudome N; Iwase T; Hatake K Cancer Chemother Pharmacol; 2008 Jun; 62(1):159-64. PubMed ID: 17882419 [TBL] [Abstract][Full Text] [Related]
11. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes. Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644 [TBL] [Abstract][Full Text] [Related]
12. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. Marty M; Cognetti F; Maraninchi D; Snyder R; Mauriac L; Tubiana-Hulin M; Chan S; Grimes D; Antón A; Lluch A; Kennedy J; O'Byrne K; Conte P; Green M; Ward C; Mayne K; Extra JM J Clin Oncol; 2005 Jul; 23(19):4265-74. PubMed ID: 15911866 [TBL] [Abstract][Full Text] [Related]
13. A Phase II trial of split, low-dose docetaxel and low-dose capecitabine: a tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer. Silva O; Lopes G; Morgenzstern D; Lobo C; Doliny P; Santos E; Abdullah S; Gautam U; Reis I; Welsh C; Slingerland J; Hurley J; Gluck S Clin Breast Cancer; 2008 Apr; 8(2):162-7. PubMed ID: 18621613 [TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. Untch M; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; von Minckwitz G J Clin Oncol; 2010 Apr; 28(12):2024-31. PubMed ID: 20308670 [TBL] [Abstract][Full Text] [Related]
15. The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer. Bisagni G; Musolino A; Panebianco M; De Matteis A; Nuzzo F; Ardizzoni A; Gori S; Gamucci T; Passalacqua R; Gnoni R; Moretti G; Boni C Cancer Chemother Pharmacol; 2013 Apr; 71(4):1051-7. PubMed ID: 23377310 [TBL] [Abstract][Full Text] [Related]
16. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer. Gajria D; Gonzalez J; Feigin K; Patil S; Chen C; Theodoulou M; Drullinsky P; D'Andrea G; Lake D; Norton L; Hudis CA; Traina TA Breast Cancer Res Treat; 2012 Jan; 131(1):111-6. PubMed ID: 21898114 [TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. Saura C; Garcia-Saenz JA; Xu B; Harb W; Moroose R; Pluard T; Cortés J; Kiger C; Germa C; Wang K; Martin M; Baselga J; Kim SB J Clin Oncol; 2014 Nov; 32(32):3626-33. PubMed ID: 25287822 [TBL] [Abstract][Full Text] [Related]
18. Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER2. Servitja S; Ramos M; Gil M; Sánchez-Rovira P; Vázquez-Estevez S; Virizuela JA; García-Estevez L; Velasco A; Tusquets I Anticancer Drugs; 2012 Feb; 23(2):239-46. PubMed ID: 22112931 [TBL] [Abstract][Full Text] [Related]
19. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. Valero V; Forbes J; Pegram MD; Pienkowski T; Eiermann W; von Minckwitz G; Roche H; Martin M; Crown J; Mackey JR; Fumoleau P; Rolski J; Mrsic-Krmpotic Z; Jagiello-Gruszfeld A; Riva A; Buyse M; Taupin H; Sauter G; Press MF; Slamon DJ J Clin Oncol; 2011 Jan; 29(2):149-56. PubMed ID: 21115860 [TBL] [Abstract][Full Text] [Related]
20. FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Ryan Q; Ibrahim A; Cohen MH; Johnson J; Ko CW; Sridhara R; Justice R; Pazdur R Oncologist; 2008 Oct; 13(10):1114-9. PubMed ID: 18849320 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]